FATE THERAPEUTICS INC Contract Liability (Deferred Revenue)
FATE THERAPEUTICS INC (FATE) had Contract Liability (Deferred Revenue) of $0 as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-08-13
- 2026-06-30: Contract with Customer, Liability, Current $0.00.
- 2026-03-31: Contract with Customer, Liability, Current $582.00K.
- 2025-12-31: Contract with Customer, Liability, Current $381.00K.
- 2025-09-30: Contract with Customer, Liability, Current $5.00K.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-13 |
| 2026-03-31 | $582.00K 10-Q · filed 2026-05-13 |
| 2025-12-31 | $381.00K 10-Q · filed 2026-08-13 |
| 2025-09-30 | $5.00K 10-Q · filed 2025-11-13 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-12 |
| 2025-03-31 | $212.00K 10-Q · filed 2025-05-13 |
| 2024-12-31 | $393.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $600.00K 10-Q · filed 2024-11-12 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-13 |
| 2024-03-31 | $159.00K 10-Q · filed 2024-05-09 |
| 2023-12-31 | $685.00K 10-K · filed 2025-03-05 |
| 2023-09-30 | $1.11M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $1.93M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $1.74M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $42.23M 10-K · filed 2024-02-26 |
| 2022-09-30 | $35.24M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $33.66M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $22.57M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $21.48M 10-K · filed 2023-02-28 |
| 2021-09-30 | $23.55M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $23.03M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $21.03M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $21.14M 10-K · filed 2022-02-28 |
| 2020-09-30 | $17.12M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $14.63M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $2.92M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $2.79M 10-K · filed 2021-02-24 |
| 2019-09-30 | $3.37M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $5.05M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $6.58M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $7.59M 10-K · filed 2020-03-02 |
| 2018-09-30 | $3.25M 10-Q · filed 2018-11-01 |
| 2018-06-30 | $1.78M 10-Q · filed 2018-08-06 |
| 2017-12-31 | $2.10M 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |